D.E. Shaw & Co’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-84,433
| Closed | -$88K | – | 4041 |
|
|
2019
Q1 | $88K | Sell |
84,433
-71,816
| -46% | -$58.5K | ﹤0.01% | 3488 |
|
|
2018
Q4 | $117K | Sell |
156,249
-171,920
| -52% | -$259K | ﹤0.01% | 3625 |
|
|
2018
Q3 | $696K | Buy |
328,169
+1,900
| +0.6% | +$4.55K | ﹤0.01% | 2920 |
|
|
2018
Q2 | $754K | Buy |
326,269
+19,506
| +6% | +$56.8K | ﹤0.01% | 2871 |
|
|
2018
Q1 | $976K | Buy |
306,763
+25,833
| +9% | +$71.2K | ﹤0.01% | 2507 |
|
|
2017
Q4 | $1.15M | Buy |
280,930
+122,914
| +78% | +$535K | ﹤0.01% | 2497 |
|
|
2017
Q3 | $714K | Buy |
158,016
+102,549
| +185% | +$415K | ﹤0.01% | 2706 |
|
|
2017
Q2 | $185K | Buy |
55,467
+33,623
| +154% | +$140K | ﹤0.01% | 3207 |
|
|
2017
Q1 | $201K | Buy |
+21,844
| New | +$192K | ﹤0.01% | 3124 |
|
|
2015
Q4 | – | Sell |
-18,112
| Closed | -$300K | – | 4147 |
|
|
2015
Q3 | $300K | Buy |
18,112
+8,557
| +90% | +$172K | ﹤0.01% | 3348 |
|
|
2015
Q2 | $215K | Buy |
+9,555
| New | +$236K | ﹤0.01% | 3557 |
|
|
2013
Q4 | – | Sell |
-47,733
| Closed | -$731K | – | 4951 |
|
|
2013
Q3 | $731K | Buy |
+47,733
| New | +$884K | ﹤0.01% | 3311 |
|
D.E. Shaw & Co's OMED Position: Q2 2019 in Review
D.E. Shaw & Co sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 84,433 shares — an estimated $88K sold.
D.E. Shaw & Co first reported a position in OMED in Q3 2013 and held it in 12 quarters. The position peaked at $1.15M in Q4 2017. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- D.E. Shaw & Co reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- D.E. Shaw & Co sold 84,433 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $88K.
- D.E. Shaw & Co first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 12 quarters.
- D.E. Shaw & Co's OncoMed Pharmaceuticals, Inc. position peaked at $1.15M in Q4 2017.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on D.E. Shaw & Co's 13F filing for Q2 2019, filed 14 Aug 2019.